Skip to main content
PMC home page
Archives of Disease in Childhood logoLink to Archives of Disease in Childhood
. 1991 Jan;66(1 Spec No):55–58. doi: 10.1136/adc.66.1_spec_no.55

Prolonged low dose indomethacin for persistent ductus arteriosus of prematurity.

J M Rennie 1, R W Cooke 1
PMCID: PMC1590349  PMID: 1996894

Abstract

A total of 121 infants who required indomethacin for persistent ductus arteriosus in Liverpool and Cambridge over a four year period were randomised to receive either 0.1 mg/kg daily for six days or 0.2 mg/kg every 12 hours for three doses. The groups were of similar birth weight and gestational and postnatal age, though those treated with a low dose were by chance receiving a higher percentage of oxygen at the start of treatment and there were more deaths from bronchopulmonary dysplasia in this group. Of 59 infants treated with the prolonged course 53 (90%) responded initially to indomethacin compared with 48 of 62 (77%) treated conventionally--a difference of 13% (95% confidence interval for the difference 0 to 26%). Of the 53 responders 11 (21%) relapsed after low dose indomethacin, whereas after the shorter course 19 of 48 (40%) relapsed. This difference was significant (95% confidence intervals 3 to 37%). Side effects, mainly gastrointestinal haemorrhage, were similar in both groups. Significantly fewer infants experienced a rise in serum creatinine or urea concentration after treatment with low dose indomethacin. A prolonged low dose course of indomethacin offers advantages over conventional treatment.

Full text

PDF
55

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Alpert B. S., Lewins M. J., Rowland D. W., Grant M. J., Olley P. M., Soldin S. J., Swyer P. R., Coceani F., Rowe R. D. Plasma indomethacin levels in preterm newborn infants with symptomatic patent ductus arteriosus--clinical and echocardiographic assessments of response. J Pediatr. 1979 Oct;95(4):578–582. doi: 10.1016/s0022-3476(79)80774-x. [DOI] [PubMed] [Google Scholar]
  2. Bhat R., Vidyasagar D., Vadapalli M., Whalley C., Fisher E., Hastreiter A., Evans M. Disposition of indomethacin in preterm infants. J Pediatr. 1979 Aug;95(2):313–316. [PubMed] [Google Scholar]
  3. Brash A. R., Hickey D. E., Graham T. P., Stahlman M. T., Oates J. A., Cotton R. B. Pharmacokinetics of indomethacin in the neonate. Relation of plasma indomethacin levels to response of the ductus arteriosus. N Engl J Med. 1981 Jul 9;305(2):67–72. doi: 10.1056/NEJM198107093050203. [DOI] [PubMed] [Google Scholar]
  4. Cowan F. Indomethacin, patent ductus arteriosus, and cerebral blood flow. J Pediatr. 1986 Aug;109(2):341–344. doi: 10.1016/s0022-3476(86)80398-5. [DOI] [PubMed] [Google Scholar]
  5. Evans D. H., Levene M. I., Archer L. N. The effect of indomethacin on cerebral blood-flow velocity in premature infants. Dev Med Child Neurol. 1987 Dec;29(6):776–782. doi: 10.1111/j.1469-8749.1987.tb08823.x. [DOI] [PubMed] [Google Scholar]
  6. Firth J., Pickering D. Timing of indomethacin therapy in persistent ductus. Lancet. 1980 Jul 19;2(8186):144–144. doi: 10.1016/s0140-6736(80)90023-9. [DOI] [PubMed] [Google Scholar]
  7. Gardner M. J., Altman D. G. Confidence intervals rather than P values: estimation rather than hypothesis testing. Br Med J (Clin Res Ed) 1986 Mar 15;292(6522):746–750. doi: 10.1136/bmj.292.6522.746. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Gersony W. M., Peckham G. J., Ellison R. C., Miettinen O. S., Nadas A. S. Effects of indomethacin in premature infants with patent ductus arteriosus: results of a national collaborative study. J Pediatr. 1983 Jun;102(6):895–906. doi: 10.1016/s0022-3476(83)80022-5. [DOI] [PubMed] [Google Scholar]
  9. Hammerman C., Strates E., Valaitis S. The silent ductus: its precursors and its aftermath. Pediatr Cardiol. 1986;7(3):121–127. doi: 10.1007/BF02424985. [DOI] [PubMed] [Google Scholar]
  10. Hanigan W. C., Kennedy G., Roemisch F., Anderson R., Cusack T., Powers W. Administration of indomethacin for the prevention of periventricular-intraventricular hemorrhage in high-risk neonates. J Pediatr. 1988 Jun;112(6):941–947. doi: 10.1016/s0022-3476(88)80224-5. [DOI] [PubMed] [Google Scholar]
  11. Krueger E., Mellander M., Bratton D., Cotton R. Prevention of symptomatic patent ductus arteriosus with a single dose of indomethacin. J Pediatr. 1987 Nov;111(5):749–754. doi: 10.1016/s0022-3476(87)80262-7. [DOI] [PubMed] [Google Scholar]
  12. Käpä P., Lanning P., Koivisto M. Early closure of patent ductus arteriosus with indomethacin in preterm infants with idiopathic respiratory distress syndrome. Acta Paediatr Scand. 1983 Mar;72(2):179–184. doi: 10.1111/j.1651-2227.1983.tb09693.x. [DOI] [PubMed] [Google Scholar]
  13. Leonhardt A., Isken V., Kühl P. G., Seyberth H. W. Prolonged indomethacin treatment in preterm infants with symptomatic patent ductus arteriosus: efficacy, drug level monitoring, and patient selection. Eur J Pediatr. 1987 Mar;146(2):140–144. doi: 10.1007/BF02343219. [DOI] [PubMed] [Google Scholar]
  14. Mahony L., Caldwell R. L., Girod D. A., Hurwitz R. A., Jansen R. D., Lemons J. A., Schreiner R. L. Indomethacin therapy on the first day of life in infants with very low birth weight. J Pediatr. 1985 May;106(5):801–805. doi: 10.1016/s0022-3476(85)80361-9. [DOI] [PubMed] [Google Scholar]
  15. Mahony L., Carnero V., Brett C., Heymann M. A., Clyman R. I. Prophylactic indomethacin therapy for patent ductus arteriosus in very-low-birth-weight infants. N Engl J Med. 1982 Mar 4;306(9):506–510. doi: 10.1056/NEJM198203043060903. [DOI] [PubMed] [Google Scholar]
  16. Mellander M., Leheup B., Lindstrom D. P., Palme C., Graham T. P., Jr, Stahlman M. T., Cotton R. B. Recurrence of symptomatic patent ductus arteriosus in extremely premature infants, treated with indomethacin. J Pediatr. 1984 Jul;105(1):138–143. doi: 10.1016/s0022-3476(84)80380-7. [DOI] [PubMed] [Google Scholar]
  17. Ment L. R., Duncan C. C., Ehrenkranz R. A., Kleinman C. S., Taylor K. J., Scott D. T., Gettner P., Sherwonit E., Williams J. Randomized low-dose indomethacin trial for prevention of intraventricular hemorrhage in very low birth weight neonates. J Pediatr. 1988 Jun;112(6):948–955. doi: 10.1016/s0022-3476(88)80225-7. [DOI] [PubMed] [Google Scholar]
  18. Ramsay J. M., Murphy D. J., Jr, Vick G. W., 3rd, Courtney J. T., Garcia-Prats J. A., Huhta J. C. Response of the patent ductus arteriosus to indomethacin treatment. Am J Dis Child. 1987 Mar;141(3):294–297. doi: 10.1001/archpedi.1987.04460030072028. [DOI] [PubMed] [Google Scholar]
  19. Rennie J. M., Doyle J., Cooke R. W. Early administration of indomethacin to preterm infants. Arch Dis Child. 1986 Mar;61(3):233–238. doi: 10.1136/adc.61.3.233. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Rhodes P. G., Ferguson M. G., Reddy N. S., Joransen J. A., Gibson J. Effects of prolonged versus acute indomethacin therapy in very low birth-weight infants with patent ductus arteriosus. Eur J Pediatr. 1988 Jun;147(5):481–484. doi: 10.1007/BF00441971. [DOI] [PubMed] [Google Scholar]
  21. Rudd P., Montanez P., Hallidie-Smith K., Silverman M. Indomethacin treatment for patent ductus arteriosus in very low birthweight infants: double blind trial. Arch Dis Child. 1983 Apr;58(4):267–270. doi: 10.1136/adc.58.4.267. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Seyberth H. W., Knapp G., Wolf D., Ulmer H. E. Introduction of plasma indomethacin level monitoring and evaluation of an effective threshold level in very low birth weight infants with symptomatic patent ductus arteriosus. Eur J Pediatr. 1983 Dec;141(2):71–76. doi: 10.1007/BF00496793. [DOI] [PubMed] [Google Scholar]
  23. Seyberth H. W., Müller H., Wille L., Plückthun H., Wolf D., Ulmer H. E. Recovery of prostaglandin production associated with reopening of the ductus arteriosus after indomethacin treatment in preterm infants with respiratory distress syndrome. Pediatr Pharmacol (New York) 1982;2(2):127–141. [PubMed] [Google Scholar]
  24. Seyberth H. W., Rascher W., Hackenthal R., Wille L. Effect of prolonged indomethacin therapy on renal function and selected vasoactive hormones in very-low-birth-weight infants with symptomatic patent ductus arteriosus. J Pediatr. 1983 Dec;103(6):979–984. doi: 10.1016/s0022-3476(83)80736-7. [DOI] [PubMed] [Google Scholar]
  25. Vert P., Bianchetti G., Marchal F., Monin P., Morselli P. L. Effectiveness and pharmacokinetics of indomethacin in premature newborns with patent ductus arteriosus. Eur J Clin Pharmacol. 1980 Jul;18(1):83–88. doi: 10.1007/BF00561483. [DOI] [PubMed] [Google Scholar]
  26. Vincer M., Allen A., Evans J., Nwaesei C., Stinson D., Rees E., Fraser A. Early intravenous indomethacin prolongs respiratory support in very low birth weight infants. Acta Paediatr Scand. 1987 Nov;76(6):894–897. doi: 10.1111/j.1651-2227.1987.tb17260.x. [DOI] [PubMed] [Google Scholar]

Articles from Archives of Disease in Childhood are provided here courtesy of BMJ Publishing Group

RESOURCES